NCT07660939
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Recruiting · Phase 1 · Peking University First Hospital · registry updated 2026-09-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma. Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment. The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.
Inclusion
- Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.
- Healthy volunteers eligible for PET/CT imaging may also be enrolled.
- Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.
- Ability to undergo PET/CT imaging procedures.
- Ability to understand the study requirements and provide written informed consent.
Exclusion
- History of other active malignant tumors, unless considered clinically insignificant by the investigator.
- Pregnant or breastfeeding women.
- Inability to understand study procedures or comply with imaging examinations.
- Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.